Skip to nav Skip to content
Facebook Twitter LinkedIn Email

To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses here.

Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA

Ending of the PHE: Overview & Implications for Surveillance, Infection Prevention & Control 
Brendan Jackson, MD, MPH
CDR, U.S. Public Health Service
COVID-19 Response Clinical Team, Late Sequelae Unit
U.S. Centers for Disease Control and Prevention

Michael Stevens, MD, MPH, FSHEA, FIDSA, FACP 
System Healthcare Epidemiologist
Associate CQO for Infection Prevention & Antimicrobial Stewardship
WVU Health System 
Professor of Internal Medicine & Public Health, WVU

Availability and Commercialization of COVID Vaccines and Treatment
Meghan E. Pennini, PhD
Director, Therapeutics 
HHS Coordination Operations and Response Element (H-CORE) 
Administration for Strategic Preparedness and Response
U.S. Department of Health and Human Services

Moving from Emergency Use Authorization to Approval of COVID-19 Treatments: Paxlovid Update
John Farley, MD, MPH
Director, Office of Infectious Diseases 
Office of New Drugs, Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Q&A and Discussion 
All panel members plus:
Alex J. Kallen, MD, MPH 
Chief, Prevention and Response Branch
Division of Healthcare Quality Promotion
U.S. Centers for Disease Control and Prevention

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.